Shots:
- Jazz Pharmaceuticals has entered into a global license agreement with Saniona to develop SAN2355 for epilepsy & other potential indications
- As per the deal, Jazz will lead & fund development, regulatory filings, & global commercialization in exchange for $42.5M upfront, ~$192.5M in development & regulatory milestones (incl. $7.5M at P-I initiation), ~$800M in commercial milestones, & tiered royalties from mid-single to low-double digits on net sales
- SAN2355, a preclinical small molecule, selectively activates Kv7.2/Kv7.3 potassium channels for seizure suppression, while avoiding activation of other Kv7-subtypes
Ref: Jazz Pharmaceuticals| Image: Jazz Pharmaceuticals and Saniona | Press Release
Related News:- Jazz Pharmaceuticals Reports the US FDA’s sNDA Acceptance and Priority Review of Zepzelca + Atezolizumab for ES-SCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
